ASCO: Rusfertide Inches Toward FDA Filing With Positive 32-Week Data

 
• By Alaric DeArment

Takeda/Protagonist are awaiting 52-week data to confirm the results from the VERIFY trial of the drug in polycythemia vera.

(Alaric DeArment)

Takeda Pharmaceutical and partner Protagonist Therapeutics are now awaiting 52-week data from their registrational trial of rusfertide in polycythemia vera (PV) patients dependent on phlebotomy, after which the drug will be ready for a US Food and Drug Administration filing.

Key Takeaways
  • Takeda/Protagonist presented positive 32-week data in the plenary session at ASCO for rusfertide in polycythemia vera, highlighting findings like the lower rate of cancers in the treatment group versus the placebo arm.

The Osaka, Japan-based drugmaker and the Newark, Calif.-based biotech presented 32-week data from the Phase III VERIFY trial in the...

More from ASCO

In Brief: Sanofi Cements Support For Adagene

 
• By Kevin Grogan

Deal Snapshot: The French drugmaker has been shifting its investments away from cancer to focus on immunology and inflammation but it continues to seek out interesting early-stage oncology assets.

J&J’s Trispecific Antibody For Myeloma Offers Improved Safety, Potency Over Bispecifics

 
• By Alaric DeArment

The drugmaker presented data from its Phase I study of JNJ-79635322 at ASCO and EHA showing a 100% response rate in BCMA- and GPRC5D-naïve patients.

ASCO: Pushing The Frontiers Of ADCs

 
• By Mary Jo Laffler

Antibody-drug conjugates are a major part of the oncology pipeline, and data presented at the American Society of Clinical Oncology meeting highlight the emergence of new technologies.

Innovent Builds Metabolic Pipeline While Retaining Oncology Backbone

 
• By Xu Hu

Innovent presented data on multiple pipeline assets at ASCO, including promising OS results for its first-in-class anti-PD-1/IL-2α-bias bispecific. The Chinese firm is also continuing to build out its metabolic disease portfolio and consider its partnering strategies, its CEO tells Scrip.

More from Blood and Clotting